Keyword: UCB

After a two-and-a-half-year wait for impulse-control warnings on six dopamine drugs, a watchdog group sued to force FDA action.

A judge questioned the Justice Department's motives for dismissing whistleblower allegations that UCB paid kickbacks to boost Cimzia scripts.

On its second try, Evenity won approval only in postmenopausal women at high risk of bone fracture—and with a boxed warning.

The UCB-sponsored fledgling initiative to create a clinical care pathway for women with IBD who are considering pregnancy gets its first-ever awareness campaign.

UCB's new mobile app is built specifically for Parkinson’s disease with a virtual health assistant named April.

Amgen osteoporosis drug Prolia is working to appeal to menopausal women with a new TV ad, but it's leaving behind its celebrity spokeswoman.

MyHealthTeams specialized social networks are adding pharma-sponsored resource centers with its most recent in spondyloarthritis.

UCB is sponsoring an effort to create a clinical care standard for women with inflammatory bowel disease (IBD) before, during and after pregnancy.

Biogen and UCB are already rumored to be eyeing an Acorda buyout. But one analyst thinks a host of other major players could join their ranks.

Earlier this month, reports said Acorda could be scouting buyers. And now, rumors are swirling as to who those potential bidders might be.